Mirum reported $186 million in third-quarter product sales and raised its full-year forecast to $715–$720 million. Pipeline studies and launches could add growth, but those gains are not certain yet, so current sales and the higher forecast support a favorable read.
Mirum’s existing medicines are bringing in sales, and Etebriose has started its U.S. launch. Positive study results may lead to more approvals or broader uses, but those gains are not certain yet. The reported sales and higher company forecast support the favorable read.
Follow Mirum Pharmaceuticals (MIRM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MIRM